Practice – Compromise of action. The new immunotherapy treatment proposed by the claimant's oncologist was not precluded from being sought for payment under the terms of the compromise agreement between the parties. Accordingly, the Queen's Bench Division allowed the claimant's application seeking a declaration that the defendant company continue to pay the private costs of immunotherapy treatment pursuant to the compromise agreement.